These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 3905048

  • 1. The biochemical pharmacology of thromboxane synthase inhibition in man.
    FitzGerald GA, Reilly IA, Pedersen AK.
    Circulation; 1985 Dec; 72(6):1194-201. PubMed ID: 3905048
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Selective and nonselective inhibition of thromboxane formation.
    FitzGerald GA, Oates JA.
    Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
    [Abstract] [Full Text] [Related]

  • 4. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
    Fitzgerald DJ, Fragetta J, FitzGerald GA.
    J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
    [Abstract] [Full Text] [Related]

  • 5. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 6. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J, Mehta P, Lawson DL, Ostrowski N, Brigmon L.
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [Abstract] [Full Text] [Related]

  • 7. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
    Varfolomeev SD, Lakin KM, Mevkh AT, Novikova NV, Rukazenkov IuZ.
    Dokl Akad Nauk SSSR; 1985 Sep; 282(1):194-6. PubMed ID: 3928305
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
    Moncada S, Vane JR.
    Pharmacol Rev; 1978 Sep; 30(3):293-331. PubMed ID: 116251
    [No Abstract] [Full Text] [Related]

  • 9. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production.
    Hornby EJ, Skidmore IF.
    Biochem Pharmacol; 1982 Mar 15; 31(6):1158-60. PubMed ID: 7200773
    [No Abstract] [Full Text] [Related]

  • 10. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.
    Bunting S, Moncada S, Vane JR.
    Br Med Bull; 1983 Jul 15; 39(3):271-6. PubMed ID: 6354352
    [No Abstract] [Full Text] [Related]

  • 11. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM, Makarov VA, Novikova NV, Tret'iak VM, Rukazenkov IuE.
    Farmakol Toksikol; 1984 Jul 15; 47(2):67-79. PubMed ID: 6425078
    [No Abstract] [Full Text] [Related]

  • 12. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ, Mayo G, Price P, FitzGerald GA.
    N Engl J Med; 1991 Oct 17; 325(16):1137-41. PubMed ID: 1891022
    [Abstract] [Full Text] [Related]

  • 13. Platelet function and biosynthesis of prostacyclin and thromboxane A2 in whole blood after aspirin administration in human subjects.
    Mehta JL, Mehta P, Lopez L, Ostrowski N, Aguila E.
    J Am Coll Cardiol; 1984 Oct 17; 4(4):806-11. PubMed ID: 6384329
    [Abstract] [Full Text] [Related]

  • 14. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
    FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR.
    J Clin Invest; 1983 Mar 17; 71(3):676-88. PubMed ID: 6338043
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA, Brash AR, Oates JA, Pedersen AK.
    J Clin Invest; 1983 Oct 17; 72(4):1336-43. PubMed ID: 6355181
    [Abstract] [Full Text] [Related]

  • 17. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb 17; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation.
    Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EF, Lefer AM.
    Proc Natl Acad Sci U S A; 1979 Jun 17; 76(6):2566-70. PubMed ID: 288046
    [Abstract] [Full Text] [Related]

  • 19. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB, Araki H, Lefer AM.
    Circulation; 1980 Dec 17; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [Abstract] [Full Text] [Related]

  • 20. New trends in thromboxane and prostacyclin modulators.
    Dogné JM, de Leval X, Delarge J, David JL, Masereel B.
    Curr Med Chem; 2000 Jun 17; 7(6):609-28. PubMed ID: 10702629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.